Stock Events

Mineralys Therapeutics 

$13.62
5
-$0.1-0.69% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
617.11M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

5
NOV
Earnings
 

Earnings

5NovExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-0.89
-0.59
-0.3
0
Expected EPS
-0.863333
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MLYS. It's not an investment recommendation.
Alphabet
77346
GOOGL
Apple
67415
AAPL
Microsoft
62824
MSFT
Amazon
58558
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Ardelyx
ARDX
Mkt Cap1.45B
Ardelyx focuses on kidney and cardiovascular diseases, directly competing in the same therapeutic areas as Mineralys Therapeutics.
Aurinia Pharmaceuticals
AUPH
Mkt Cap973.77M
Aurinia Pharmaceuticals develops drugs for kidney diseases and lupus, overlapping with Mineralys' focus on renal health.
Regulus Therapeutics
RGLS
Mkt Cap109.98M
Regulus Therapeutics is involved in developing treatments for kidney diseases, making it a direct competitor in the nephrology space.
Trevena
TRVN
Mkt Cap90.62M
Trevena, Inc. develops therapies for central nervous system disorders but has interests in expanding to other areas including treatments that could compete with Mineralys.
FibroGen
FGEN
Mkt Cap36.71M
FibroGen works on therapies for kidney diseases, directly competing with Mineralys in the nephrology market.
Akebia Therapeutics
AKBA
Mkt Cap325.95M
Akebia Therapeutics focuses on kidney disease and anemia, areas that overlap with Mineralys Therapeutics' interests.
Amarin
AMRN
Mkt Cap257.19M
Amarin Corporation focuses on cardiovascular health, which can be indirectly competitive with Mineralys' focus on conditions that affect the heart and kidneys.
Galmed Pharmaceuticals
GLMD
Mkt Cap2.18M
Galmed Pharmaceuticals works on liver diseases and metabolic disorders, which can intersect with Mineralys' therapeutic areas in terms of metabolic health and its impact on kidney function.

Analyst Ratings

30$Average Price Target
The highest estimate is $30.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Show more...
CEO
Employees
28
Country
US
ISIN
US6031701013

Listings

XNAS
US
MLYS